The role of circadian rhythm in the pathogenesis of colorectal cancer

Current Colorectal Cancer Reports

Volumn 6, Issue 2, 2010, Pages 74-82

  Wood, Patricia A ^a   Yang, Xiaoming ^a   Hrushesky, William J M ^a,b,c  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c The Department of Mechanical Engineering   (United States)

Author keywords

Circadian clock; Colorectal cancer; Melatonin; Period

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BETA CATENIN; CASEIN KINASE I; CHECKPOINT KINASE 2; CYCLIN D; CYCLOPHOSPHAMIDE; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUOROURACIL; GAMMA INTERFERON; IRINOTECAN; MELATONIN; MYC PROTEIN; PER1 PROTEIN; PER2 PROTEIN; PER3 PROTEIN; PROTEIN; PROTEIN BMAL1; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CIRCADIAN RHYTHM; COLON ADENOCARCINOMA; COLON ADENOMA; COLORECTAL ADENOMA; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG CYTOTOXICITY; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; GAMMA IRRADIATION; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; HORMONE RECEPTOR INTERACTION; HUMAN; INTESTINE MOTILITY; INTESTINE SECRETION; INTRACELLULAR SIGNALING; LEUKEMIA; MOLECULAR CLOCK; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; RECTUM CARCINOMA; REVIEW; THYMOCYTE;

EID: 79952706156     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-010-0045-2     Document Type: Review

References (54)

1. Ko CH, Takahashi JS: Molecular components of the mammalian circadian clock. Hum Mol Genet 2006, 15 Spec No 2:R271-R277. (Pubitemid 44446803)
2. Matsuo T, Yamaguchi S, Mitsui S, et al.: Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003, 302:255-259. (Pubitemid 37248750)
3. Bjarnason GA, Jordan RC, Wood PA, et al.: Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 2001, 158:1793-1801. (Pubitemid 32422944)
4. Grechez-Cassiau A, Rayet B, Guillaumond F, et al.: The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem 2008, 283:4535-4542.
5. Wood PA, Du-Quiton J, You S, et al.: Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 2006, 5:2023-2033. (Pubitemid 44336574)
6. Gorbacheva VY, Kondratov RV, Zhang R, et al.: Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A 2005, 102:3407-3412. (Pubitemid 40328058)
7. Kang TH, Reardon JT, Kemp M, et al.: Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci U S A 2009, 106(8):2864-2867. This was the first study to show that the expression of a DNA repair enzyme is circadian clock controlled.
8. Hoogerwerf WA, Sinha M, Conesa A, et al.: Transcriptional profiling of mRNA expression in the mouse distal colon. Gastroenterology 2008, 135:2019-2029.
9. Sjoblom T, Jones S, Wood LD, et al.: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274. (Pubitemid 44571966)
10. Forbes SA, Bhamra G, Bamford S, et al.: The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008, Chapter 10:Unit 10.11.
11. Fu L, Pelicano H, Liu J, et al.: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002, 111:41-50.
12. Wood PA, Yang X, Taber A, et al.: Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res 2008, 6:1786-1793. This article shows that Per2 has a tumor suppression function in a CRC animal model
13. Krugluger W, Brandstaetter A, Kallay E, et al.: Regulation of genes of the circadian clock in human colon cancer: reduced Period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res 2007, 67:7917-7922. (Pubitemid 47281388)
14. Zeman M, Vician M, Monosikova J, et al.: Deregulated expression of Per2 gene in human colorectal cancer. Molec Med Rep 2008, 1:599-603.
15. Mostafaie N, Kallay E, Sauerzapf E, et al.: Correlated downregulation of estrogen receptor beta and the circadian clock gene Per2 in human colorectal cancer. Mol Carcinog 2009, 48:642-647.
16. Iacobelli S, Innominato PF, Piantelli M, et al.: Tumor clock protein PER2 as a determinant of survival in patients receiving oxaliplatin-5-FU-leucovorin as first-line chemotherapy for metastatic colorectal cancer [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):11032.
17. Gery S, Gombart AF, Yi WS, et al.: Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 2005, 106:2827-2836. (Pubitemid 41510760)
18. Gery S, Komatsu N, Baldjyan L, et al.: The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006, 22:375-382.
19. Cao Q, Gery S, Dashti A, et al.: A role for the clock gene Per1 in prostate cancer. Cancer Res 2009, 69:7619-7625.
20. Giacchetti S, Bjarnason G, Garufi C, et al.: Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as firstline chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006, 24:3562-3569. (Pubitemid 46630527)
21. Yang X, Wood PA, Ansell CM, et al.: Beta-catenin induces beta- TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem 2009, 145:289-297.
22. You S, Wood PA, Xiong Y, et al.: Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat 2005, 91:47-60. (Pubitemid 40684938)
23. Yang X, Wood PA, Oh EY, et al.: Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 2008, 117 (2):423-431.
24. Gery S, Virk RK, Chumakov K, et al.: The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007, 26:7916-7920. This article shows that PER2 destabilizes ERα protein.
25. Cai W, Rambaud J, Teboul M, et al.: Expression levels of estrogen receptor b are modulated by components of the molecular clock. Mol Cell Biol 2008, 28:784-793.
26. Coao Q, Gery S, Dashti A, et al.: A role for the clock gene Per1 in prostate cancer. Cancer Res 2009, 69:7619-7625.
27. Wang C, Wen M, Wang H, et al.: Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation 2008, 118:2166-2173.
28. Liu J, Mankani G, Shi X, et al.: The circadian clock Period 2 gene regulates gamma interferon production of NK cells in host response to lipopolysaccharide-induced endotoxic shock. Infect Immun 2006, 74:4750-4756. (Pubitemid 44157263)
29. Farriol M, Venereo Y, Orta X, et al.: In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000, 20:21-24.
30. Garcia-Navarro A, Gonzalez-Puga C, Escames G, et al.: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007, 43:195-205. (Pubitemid 47078925)
31. Winczyk K, Pawlikowski M, Lawnicka H, et al.: Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol- 2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo. Neuro Endocrinol Lett 2002, 23 (Suppl 1):50-54. (Pubitemid 34495382)
32. Anisimov VN, Popovich IG, Zabezhinski MA: Melatonin and colon carcinogenesis: I. inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 1997, 18:1549-1553. (Pubitemid 28134778)
33. Tanaka T, Yasui Y, Tanaka M, et al.: Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009, 177:128-136. This article shows that melatonin has an inhibitory effect on colonic adenocarcinoma development in an animal model.
34. Schernhammer ES, Berrino F, Krogh V, et al.: Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2008, 100:898-905. (Pubitemid 351881952)
35. Khoory R, Stemme D: Plasma melatonin levels in patients suffering from colorectal carcinoma. J Pineal Res 1988, 5:251-258.
36. Vician M, Zeman M, Herichova I, et al.: Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. J Pineal Res 1999, 27:164-169. (Pubitemid 29487961)
37. Schernhammer ES, Laden F, Speizer FE, et al.: Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003, 95:825-828. (Pubitemid 36798430)
38. Kloog I, Haim A, Stevens RG, et al.: Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men. Chronobiol Int 2009, 26:108-125.
39. Cerea G, Vaghi M, Ardizzoia A, et al.: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 2003, 23:1951-1954. (Pubitemid 36750873)
40. Barni S, Lissoni P, Cazzaniga M, et al.: A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995, 52:243-245.
41. Blask DE, Sauer LA, Dauchy RT, et al.: Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999, 59:4693-4701. (Pubitemid 29428978)
42. Filipski E, Innominato PF, Wu M, et al.: Effect of light and food schedules on liver and tumor molecular clock in mice. J Natl Cancer Inst 2005, 97(7):507-517. (Pubitemid 40590432)
43. Filipski E, King VM, Li X, et al.: Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002, 94:690-697. (Pubitemid 34552490)
44. Toh K, Jones C, He Y, et al.: An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001, 291:1040-1043. (Pubitemid 32157412)
45. Xu Y, Padiath Q, Shapiro R, et al.: Functional consequences of a CKId mutation causing familial advanced sleep phase syndrome. Nature 2005, 434:640-644. (Pubitemid 40488555)
46. Carpen J, von Schantz M, Smits M, et al.: A silent polymorphism in the PER1 gene associates with extreme diurnal preference. J Hum Genet 2006, 51:1122-1125. (Pubitemid 44800732)
47. Carpen J, Archer S, Skene D, et al.: A single-nucleotide polymorphism in the 5?-untranslated region of the hPer2 gene is associated with diurnal preference. J Sleep Res 2005, 14:293-297. (Pubitemid 41291314)
48. Ebisawa T, Uchiyama M, Kajimura N, et al.: Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome. EMBO Rep 2001, 2:342-346. (Pubitemid 32401531)
49. Archer S, Robilliard D, Skene D, et al.: A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep 2003, 26:413-415. (Pubitemid 39610658)
50. Zhu Y, Brown HN, Zhang Y, et al.: Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 2005, 14:268-270. (Pubitemid 40165313)
51. Gaspar C, Cardoso J, Franken P, et al.: Cross-species comparison of human and mouse intestinal polyps reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. Am J Pathol 2008, 172(5):1363-1380. (Pubitemid 351671549)
52. Sabates-Bellver J, Van der Flier LG, de Palo M, et al.: Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007, 5(12):1263-1275.
53. Ki DH, Jeung HC, Park CH, et al.: Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007, 121(9):2005-2012.
54. Kaiser S, Park YK, Franklin JL, et al.: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007, 8(7):R131.